Related Experiment Video
Updated: May 5, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
20.2K
Metformin-induced hemolytic anemia.
Serap Kirkiz1, Nese Yarali, Ozlem Arman Bilir
1Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey.
Summary
Metformin, an oral antidiabetic drug, can rarely cause drug-induced hemolytic anemia. Physicians should monitor patients for this potential side effect, especially during cancer treatment.
Area of Science:
- Hematology
- Pharmacology
- Oncology
Background:
- Metformin is a widely used oral antidiabetic medication for type 2 diabetes mellitus.
- Chemotherapy regimens for acute lymphoblastic leukemia can induce hyperglycemia and insulin resistance.
Observation:
- A 17-year-old patient undergoing chemotherapy developed steroid-induced hyperglycemia.
- Metformin was initiated for hyperglycemia management.
- The patient subsequently developed hemolytic anemia with a positive direct Coombs test while on metformin.
Findings:
- Discontinuation of metformin led to the resolution of hemolytic anemia and jaundice.
- The patient did not require blood transfusions, indicating a mild to moderate presentation.
- Glucose-6-phosphate dehydrogenase levels were normal, ruling out other common causes of hemolysis.
Implications:
- This case highlights a rare but serious adverse effect of metformin: drug-induced hemolytic anemia.
- Healthcare providers should maintain a high index of suspicion for metformin-induced hemolytic anemia in patients presenting with unexplained anemia and hemolysis.
- Awareness of this potential side effect is crucial for timely diagnosis and management, particularly in vulnerable patient populations.
More Related Videos
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
998
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
998
01:01Hypersensitivity Reactions: Cytolytic Reactions
221
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
221
01:29Hyperglycemia
34
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...
34
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
958
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
958
01:15Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K